Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products

被引:62
作者
Chen, Chia-Hao [1 ]
Yang, Jyh-Chin [2 ]
Uang, Yow-Shieng [3 ]
Lin, Chun-Jung [1 ]
机构
[1] Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Dept Internal Med, Hosp & Coll Med, Taipei 100, Taiwan
[3] Taipei Med Univ, Sch Pharm, Taipei 110, Taiwan
关键词
Lovastatin; Bioavailability; Dissolution; Crystallinity; Red yeast rice; PURPUREUS WENT RICE; MONASCUS-PURPUREUS; REDUCTASE INHIBITORS; CHOLESTEROL; EFFICACY; SIMVASTATIN; XUEZHIKANG; PREVENTION; EXTRACT; EVENTS;
D O I
10.1016/j.ijpharm.2013.01.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lovastatin, categorized as a class II compound according to the Biopharmaceutics Classification System, is mainly responsible for the blood cholesterol lowering effect of red yeast rice (RYR). The aim of this study was to compare the dissolution rate, physical state, and oral bioavailability of lovastatin in three RYR products (LipoCol Forte, Cholestin, or Xuezhikang) to those of two lovastatin tablets (Mevacor or Lovasta). The results showed that the dissolution rate of lovastatin in various dissolution media in the registered RYR products was faster and higher than that of lovastatin in lovastatin tablets. Powder X-ray diffraction and differential scanning calorimetry patterns showed that the crystallinity of lovastatin was reduced in RYR products. In human studies, the AUC and C-max values for both lovastatin and its active metabolite, lovastatin acid, were significantly higher in volunteers receiving LipoCol Forte capsules or powder than in those receiving lovastatin tablets or powder. In addition, shorter and less variable T-max values were observed in volunteers taking LipoCol Forte than in those taking lovastatin tablets. These findings suggest that the oral bioavailability of lovastatin is significantly improved in RYR products as a result of a higher dissolution rate and reduced crystallinity. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 31 条
  • [1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT
    ALBERTS, AW
    CHEN, J
    KURON, G
    HUNT, V
    HUFF, J
    HOFFMAN, C
    ROTHROCK, J
    LOPEZ, M
    JOSHUA, H
    HARRIS, E
    PATCHETT, A
    MONAGHAN, R
    CURRIE, S
    STAPLEY, E
    ALBERSSCHONBERG, G
    HENSENS, O
    HIRSHFIELD, J
    HOOGSTEEN, K
    LIESCH, J
    SPRINGER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07): : 3957 - 3961
  • [2] [Anonymous], 2012, PACK INS MEV
  • [3] Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial
    Becker, David J.
    Gordon, Ram Y.
    Morris, Patti B.
    Yorko, Jacqueline
    Gordon, Y. Jerold
    Li, Mingyao
    Iqbal, Nayyar
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (07) : 758 - 764
  • [4] Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients A Randomized Trial
    Becker, David J.
    Gordon, Ram Y.
    Halbert, Steven C.
    French, Benjamin
    Morris, Patti B.
    Rader, Daniel J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2009, 150 (12) : 830 - U30
  • [5] FLUORIMETRIC DETERMINATION OF CRITICAL MICELLE CONCENTRATION AVOIDING INTERFERENCE FROM DETERGENT CHARGE
    CHATTOPADHYAY, A
    LONDON, E
    [J]. ANALYTICAL BIOCHEMISTRY, 1984, 139 (02) : 408 - 412
  • [6] Chen C.H., 2012, EVID-BASED COMPL ALT, V10
  • [7] Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1
    Chen, CP
    Mireles, RJ
    Campbell, SD
    Lin, J
    Mills, JB
    Xu, JHJ
    Smolarek, TA
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) : 537 - 546
  • [8] Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
    Dressman, JB
    Amidon, GL
    Reppas, C
    Shah, VP
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (01) : 11 - 22
  • [9] Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs
    Galia, E
    Nicolaides, E
    Hörter, D
    Löbenberg, R
    Reppas, C
    Dressman, JB
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (05) : 698 - 705
  • [10] Heber D, 1999, AM J CLIN NUTR, V69, P231